Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008 | Hematology Meeting Reports (formerly Haematologica Reports)

Current Issue

Vol. 2 No. 5

23 June 2009

View this Issue

Vol. 2 No. 5: New Drugs in Hematology, Bologna, Italy 5-7 October 2008

Published: 23 June 2009

Articles

Myelodysplastic syndromes

M Cazzola

https://doi.org/10.4081/hmr.v2i5.717

219

PDF: 120
- PDF
Organ damage and iron overload

E Angelucci, C Cogoni, M Pettinau, F Pilo, C Targhetta, F Zacchedu

https://doi.org/10.4081/hmr.v2i5.718

302

PDF: 1414
- PDF
Progress in the management of iron overload in erytrocyte disorders

MD Cappellini, E Cassinerio, L Zanaboni, G Fabio, P Pattoneri

https://doi.org/10.4081/hmr.v2i5.719

246

PDF: 1714
- PDF
Ph positive-leukemias

F Guilhot, L Roy, J Guilhot, PJ Saulnier, JM Gombert, A Turhan

https://doi.org/10.4081/hmr.v2i5.720

183

PDF: 177
- PDF
Thyrosin kinase inhibitors: nilotinib

F Castagnetti, F Palandri, G Gugliotta, A Poerio, M Amabile, S Soverini, G Martinelli, M Baccarani, G Rosti

https://doi.org/10.4081/hmr.v2i5.721

384

PDF: 455
- PDF
New drugs to overcome meccanisms of resistance in Ph+ leukemia: bosutinib

G Martinelli, I Iacobucci, D Cilloni, P Giannoulia, S Soverini, PP Piccaluga, C Papayannidis, S Paolini, C Terragna

https://doi.org/10.4081/hmr.v2i5.722

236

PDF: 225
- PDF
Peripheral T-cell lymphomas

SA Pileri, C Agostinelli, C Campidelli, F Bacci, E Sabattini, A Pileri Jr, PP Piccaluga

https://doi.org/10.4081/hmr.v2i5.723

277

PDF: 616
- PDF
Histone deacetylase inhibitors: SAHA (Vorinostat). A treatment option for advanced cutaneous T-cell lymphoma

M Duvic

https://doi.org/10.4081/hmr.v2i5.724

261

PDF: 2326
- PDF
A Phase II international, multicenter study of oral panobinostat (LBH589) in patients with refractory cutaneous T-cell lymphoma

MG Bernengo, F Vanaclocha, M Duvic, T Kuzel, F Kerdel, L Pinter-Brown, A Bosly, C Okada, D Breneman, PL Zinzani, J Becker, L Hughey, M Ardaiz, J Zain, L Zhang

https://doi.org/10.4081/hmr.v2i5.725

203

PDF: 202
- PDF
Chronic lymphocytic leukemia

F Caligaris-Cappio

https://doi.org/10.4081/hmr.v2i5.727

213

PDF: 2549
- PDF
Monoclonal antibodies (update): CD20, rituximab

C Hagenbeek

https://doi.org/10.4081/hmr.v2i5.728

213

PDF: 138
- PDF
90Y-ibritumumab tiuxetan (Zevalin)

PL Zinzani

https://doi.org/10.4081/hmr.v2i5.729

242

PDF: 363
- PDF
Update of alemtuzumab in the treatment of chronic lymphocytic leukaemia

C Dearden

https://doi.org/10.4081/hmr.v2i5.731

198

PDF: 234
- PDF
Immunotherapy with epratuzumab in B-cell non-Hodgkin’s lymphoma

P Martin, D Goldenberg, JP Leonard

https://doi.org/10.4081/hmr.v2i5.732

164

PDF: 370
- PDF
New agents for the treatment of acute myeloid leukemia: gemtuzumab ozogamicin

S Amadori

https://doi.org/10.4081/hmr.v2i5.733

180

PDF: 567
- PDF
Update on galiximab: anti-CD80 monoclonal antibody

MS Czuczman

https://doi.org/10.4081/hmr.v2i5.734

242

PDF: 260
- PDF
CMC-544 (inotuzumab ozogamicin): A CD22-targeted immunoconjugate of calicheamicin

JF DiJoseph, K Khandke, MM Dougher, DY Evans, DC Armellino, PR Hamann, NK Damle

https://doi.org/10.4081/hmr.v2i5.735

673

PDF: 2463
- PDF
Zanolimumab (HuMax-CD4®), a fully human monoclonal antibody in clinical development for cutaneous T-cell lymphoma

C Assaf

https://doi.org/10.4081/hmr.v2i5.736

288

PDF: 349
- PDF
Monoclonal antibodies (novel): humax-CD20, ofatumumab

A Hagenbeek

https://doi.org/10.4081/hmr.v2i5.737

208

PDF: 218
- PDF
Lumiliximab in chronic lymphocytic leukemia

TS Lin

https://doi.org/10.4081/hmr.v2i5.738

195

PDF: 453
- PDF
Bevacizumab as an anti-VEGF strategy in lymphoma

SJ Horning

https://doi.org/10.4081/hmr.v2i5.739

292

PDF: 193
- PDF
Individualizing therapy for the hematologic malignancies: the stuff of genes and dreams

BD Cheson

https://doi.org/10.4081/hmr.v2i5.741

210

PDF: 282
- PDF
Aurora kinase inhibitor: AS703569

A Gianella-Borradori

https://doi.org/10.4081/hmr.v2i5.742

227

PDF: 293
- PDF
From cell biology to therapy: lenalidomide in untreated multiple myeloma

A Palumbo, P Falco, F Gay, V Magarotto, F Patriarca, C Nozzoli, M Boccadoro

https://doi.org/10.4081/hmr.v2i5.744

204

PDF: 235
- PDF
HuMax-CD38, a new human CD38 monoclonal antibody, effectively mediates killing of multiple myeloma and plasma cell leukemia cells

PWHI Parren

https://doi.org/10.4081/hmr.v2i5.740

481

PDF: 611
- PDF
Pha-739358: a pan-aurora kinase inhibitor

R Paquette, N Shah, C Sawyers, G Martinelli, J Nicoll, M Chalukya

https://doi.org/10.4081/hmr.v2i5.743

257

Untitled: 0

PDF: 442
- PDF
From cell biology to therapy: lenalidomide in relapsed/refractory multiple myeloma

P Richardson, T Hideshima, C Mitsiades, R Schlossman, J Laubach, I Ghobrial, N Raje, N Munshi, K Anderson

https://doi.org/10.4081/hmr.v2i5.745

191

PDF: 293
- PDF
Bendamustine is a hybrid antimetabolite and alkylating agent offering new therapeutic options for the treatment of non-Hodgkin lymphomas

A Dreyling

https://doi.org/10.4081/hmr.v2i5.749

369

PDF: 437
- PDF
From cell biology to therapy: forodesine

M Duvic

https://doi.org/10.4081/hmr.v2i5.746

409

PDF: 766
- PDF
Flavopiridol (alvocidib) in chronic lymphocytic leukemia

TS Lin, B Fischer, KA Blum, M Brooker-McEldowney, ME Moran, LA Andritsos, JM Flynn, MA Phelps, JT Dalton

https://doi.org/10.4081/hmr.v2i5.747

337

PDF: 812
- PDF
mTOR inhibitors for the treatment of lymphoma

TE Witzig

https://doi.org/10.4081/hmr.v2i5.748

215

PDF: 338
- PDF
Multiple myeloma

J San Miguel

https://doi.org/10.4081/hmr.v2i5.750

156

PDF: 105
- PDF
Proteasome inhibitors: bortezomib in multiple myeloma

M Cavo, MC Pallotti, L Pantani, A Petrucci, A Brioli, C Terragna, N Testoni, G Marzocchi, S Durante, M Ceccolini, G Perrone, P Tacchetti, E Zamagni, P Tosi, M Baccarani

https://doi.org/10.4081/hmr.v2i5.751

191

PDF: 216
- PDF
Bortezomib in lymphomas

A Goy

https://doi.org/10.4081/hmr.v2i5.752

194

PDF: 161
- PDF
Proteasome inhibitors: beyond NFKB inhibition alone and the emerging role of combination therapy in the treatment of multiple myeloma

P Richardson, C Mitsiades, J Laubach, C Conant, T Hideshima, D Chauhan, R Schlossman, I Ghobrial, N Munshi, KC Anderson

https://doi.org/10.4081/hmr.v2i5.753

418

PDF: 236
- PDF
Novel proteasome inhibitors

P Tosi, MC Pallotti, L Pantani, A Petrucci

https://doi.org/10.4081/hmr.v2i5.754

218

PDF: 335
- PDF
Decitabine in myeloid malignancies

HI Saba

https://doi.org/10.4081/hmr.v2i5.755

190

PDF: 831
- PDF
J-L. Harousseau Tipifarnib in hematologic malignancies

JL Harousseau

https://doi.org/10.4081/hmr.v2i5.756

184

PDF: 249
- PDF
Is there a role for immunotherapy in Hodgkin’s disease?

B Böll, A Engert

https://doi.org/10.4081/hmr.v2i5.757

173

PDF: 568
- PDF
New agents for the treatment of acute myeloid leukemia: midostaurin

S Amadori

https://doi.org/10.4081/hmr.v2i5.760

234

PDF: 888
- PDF
Lestaurtinib as a FLT3 inhibitor

AK Burnett

https://doi.org/10.4081/hmr.v2i5.761

166

PDF: 179

Untitled: 0
- PDF

© PAGEPress 2008-2025 • PAGEPress^® is a registered trademark property of PAGEPress srl, Italy • VAT: IT02125780185 • Privacy